AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
HCW Biologics Inc (NASDAQ:HCWB)
0.65 USD
+0.372 133.645%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.2782 |
|---|---|
| Change | +0.372 133.645% |
| 52 W H/L (in USD) | 2.320/0.910 |
| EBITDA (in USD) | -27.097M |
| PE Ratio | -- |
| Volume | 321373597 |
| Diluted Eps TTM | -0.76 |
| Total Assets (in USD) | 28.514M |
|---|---|
| Total Liabilities (in USD) | 15.052M |
| Revenue TTM (in USD) | 3.927M |
| Cash (in USD) | 3.595M |
| Market Cap (in USD) | 41.984 M |
| Revenue Per Share TTM | 0.108 |
| Gross Profit TTM (in USD) | 4.1M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
2929 North Commerce Parkway, Miramar, FL, United States, 33025
954 842 2024
Employees: 45
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Hing C. Wong Ph.D. | Founder, CEO, Director & Sec. | 1954 |
| 2. | Ms. Rebecca Byam CPA, M.B.A. | Chief Financial Officer | 1956 |
| 3. | Dr. Peter Rhode Ph.D. | Chief Scientific Officer & VP of Clinical Operations | 1958 |
| 4. | Ms. Nicole Valdivieso Esq. | VP of Legal Affairs | NA |
| 5. | Ms. Raquel Diaz M.S. | Director of HR | NA |
| 6. | Mr. Lee D. Flowers | Sr. VP of Bus. Devel. | 1946 |
| 7. | Dr. Hing C. Wong Ph.D. | Founder, CEO, Director & Secretary | 1954 |
| 8. | Ms. Nicole Valdivieso Esq. | Vice President of Legal Affairs | NA |
| 9. | Ms. Raquel Diaz M.S. | Director of Human Resources | NA |
| 10. | Mr. Lee D. Flowers | Senior Vice President of Business Development | 1946 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-1.550 1.835% | 82.13 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-3.760 4.470% | 80.35 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+7.559 1.637% | 463.36 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-4.855 0.721% | 668.8 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -14.901M | -12.862M | -5.802M | -7.293M |
| Minority Interest | - | - | - | - |
| Net Income | -14.723M | -12.357M | -5.78M | -7.221M |
| Selling General Administrative | 8.327M | 4.976M | 2.436M | 1.803M |
| Gross Profit | 2.586M | - | 4.1M | - |
| Reconciled Depreciation | 0.718M | 0.544M | 0.596M | 0.422M |
| Ebit | -15.079M | -13.368M | -5.825M | -7.365M |
| Ebitda | -14.774M | -12.824M | -5.229M | -6.943M |
| Depreciation And Amortization | 0.305M | 0.544M | 0.596M | 0.422M |
| Operating Income | -15.079M | -13.368M | -5.825M | -7.365M |
| Other Operating Expenses | 21.801M | 13.368M | 9.924M | 7.365M |
| Interest Expense | 0.127M | 0.505M | 0M | 0M |
| Tax Provision | - | - | - | - |
| Interest Income | - | 0.505M | 0.022M | 0.072M |
| Net Interest Income | -0.127M | 0.505M | 0.022M | 0.072M |
| Income Tax Expense | -0.178M | -0.505M | -0.022M | -0.072M |
| Total Revenue | 6.722M | 0M | 4.1M | 0M |
| Total Operating Expenses | 17.665M | 13.368M | 9.924M | 7.365M |
| Cost Of Revenue | 4.136M | - | - | - |
| Total Other Income Expense Net | 0.178M | 0.505M | 0.022M | 0.072M |
| Net Income From Continuing Ops | -15.205M | -12.862M | -5.802M | -7.293M |
| Net Income Applicable To Common Shares | -14.901M | -12.862M | -7.074M | -7.783M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 28.514M | 46.809M | 53.515M | 15.398M | 10.066M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.273M | 0.196M | 1.437M | 0.655M | 0.236M |
| Total Liab | 15.052M | 9.381M | 2.322M | 1.001M | 1.066M |
| Total Stockholder Equity | 13.462M | 37.429M | 51.193M | 14.397M | 9M |
| Other Current Liab | 2.433M | 1.73M | 2.098M | 0.846M | 0.674M |
| Common Stock | 0.004M | 0.004M | 0.004M | 0M | 0M |
| Capital Stock | 0.004M | 0.004M | 0.004M | 31.116M | 18.677M |
| Retained Earnings | -70.532M | -45.538M | -30.637M | -16.719M | -9.677M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.334M | 0.393M | 0.034M | 0.034M |
| Cash | 3.595M | 22.326M | 11.731M | 8.456M | 7.356M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 8.748M | 2.956M | 2.322M | 1.001M | 1.066M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | 2.857M | -15.916M | -11.731M | -8.456M | -7.356M |
| Short Term Debt | 0.147M | 6.41M | - | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 6.452M | 6.41M | - | - | - |
| Other Stockholder Equity | 83.99M | 82.963M | 81.827M | - | - |
| Property Plant Equipment | - | 10.805M | 1.119M | 1.615M | 2.002M |
| Total Current Assets | 6.404M | 34.071M | 40.48M | 12.149M | 8.03M |
| Long Term Investments | 1.6M | 1.6M | 11.522M | 1.6M | 0M |
| Short Term Investments | 0M | 9.736M | 24.984M | - | - |
| Net Receivables | 1.536M | 0.418M | 0.133M | 2.5M | 0M |
| Long Term Debt | 6.304M | 6.41M | - | - | - |
| Inventory | - | 1.395M | 2.197M | 0.538M | - |
| Accounts Payable | 6.167M | 1.226M | 0.224M | 0.155M | 0.392M |
| Accumulated Other Comprehensive Income | - | - | -53.515M | - | - |
| Non Currrent Assets Other | 0.057M | 0.334M | 0.393M | 0.034M | 0.034M |
| Non Current Assets Total | 22.109M | 12.738M | 13.034M | 3.249M | 2.036M |
| Capital Lease Obligations | - | - | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | 24.984M | -34.972M | -0.187M | -1.46M |
| Total Cashflows From Investing Activities | 14.708M | -35.019M | -0.187M | -1.46M |
| Total Cash From Financing Activities | 6.273M | 49.269M | 11.718M | 13.447M |
| Net Income | -14.901M | -12.862M | -5.802M | -7.293M |
| Change In Cash | 10.596M | 3.275M | 1.1M | 5.221M |
| Begin Period Cash Flow | 11.731M | 8.456M | 7.356M | 2.134M |
| End Period Cash Flow | 22.326M | 11.731M | 8.456M | 7.356M |
| Total Cash From Operating Activities | -10.386M | -10.976M | -10.431M | -6.765M |
| Depreciation | 0.718M | 0.544M | 0.596M | 0.422M |
| Other Cashflows From Investing Activities | - | - | - | 0M |
| Dividends Paid | - | 2.822M | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | -0.175M | - | - | - |
| Other Cashflows From Financing Activities | 6.258M | -3.938M | 11.708M | 13.386M |
| Capital Expenditures | 10.275M | 0.047M | 0.187M | 1.46M |
| Change In Working Capital | 2.488M | 1.455M | -5.247M | 0.104M |
| Other Non Cash Items | 0.188M | 0.028M | -9.43M | - |
| Free Cash Flow | -20.661M | -11.023M | -10.618M | -8.225M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Extended Market Index | 10 months ago | 107558 |
| 2. | Bridgeway Ultra-Small Company Market | 10 months ago | 84700 |
| 3. | iShares Micro-Cap ETF | 9 months ago | 41247 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 9 months ago | 37649 |
| 5. | Fidelity Total Market Index | 10 months ago | 29023 |
| 6. | Fidelity Nasdaq Composite Index | 10 months ago | 23272 |
| 7. | Northern Trust Extended Eq Market Idx | 10 months ago | 9060 |
| 8. | NT Ext Equity Mkt Idx Fd - L | 10 months ago | 9060 |
| 9. | Fidelity Series Total Market Index | 10 months ago | 7752 |
| 10. | Spartan Total Market Index Pool E | 10 months ago | 3593 |
| 11. | 1290 VT Micro Cap K | 10 months ago | 3382 |
| 12. | ZWJ Balanced | 10 months ago | 3125 |
| 13. | State St US Extended Mkt Indx NL Cl C | 9 months ago | 3000 |
| 14. | SSgA U.S. Extended Market Index Class I | 1 year ago | 3000 |
| 15. | Spartan Extended Market Index Pool E | 10 months ago | 2954 |
| 16. | NT US Market Cap Idx Fd - L | 1 year ago | 1145 |
| 17. | Northern Trust Wilshire 5000 | 10 months ago | 1145 |
| 18. | State St US Ttl Mkt Indx SL Cl I | 9 months ago | 900 |
| 19. | SSgA U.S. Total Market Index Strategy | 1 year ago | 865 |
| 20. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 10 months ago | 368 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | HighTower Advisors, LLC | 1 year ago | 179810 |
| 2. | Honkamp Krueger Financial Services Inc | 10 months ago | 179777 |
| 3. | Geode Capital Management, LLC | 1 year ago | 134436 |
| 4. | Cresset Asset Management, LLC | 10 months ago | 131990 |
| 5. | Bridgeway Capital Management, LLC | 10 months ago | 84700 |
| 6. | BlackRock Inc | 1 year ago | 47158 |
| 7. | Vanguard Group Inc | 10 months ago | 37649 |
| 8. | AE Wealth Management LLC | 1 year ago | 30000 |
| 9. | Two Sigma Investments LLC | 10 months ago | 22640 |
| 10. | State Street Corporation | 1 year ago | 21446 |
| 11. | Northern Trust Corp | 1 year ago | 10205 |
| 12. | Tower Research Capital LLC | 1 year ago | 5669 |
| 13. | UBS Group AG | 1 year ago | 635 |
| 14. | Royal Bank of Canada | 1 year ago | 296 |
| 15. | Wells Fargo & Co | 1 year ago | 138 |
| 16. | JPMorgan Chase & Co | 1 year ago | 83 |
| 17. | Bank of America Corp | 1 year ago | 11 |
| 18. | Focused Wealth Strategies, INC. | 10 months ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
